dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorCtr Appl Toxicol
dc.date.accessioned2014-05-20T15:24:22Z
dc.date.accessioned2022-10-05T16:28:00Z
dc.date.available2014-05-20T15:24:22Z
dc.date.available2022-10-05T16:28:00Z
dc.date.created2014-05-20T15:24:22Z
dc.date.issued2004-11-12
dc.identifierBiochemical and Biophysical Research Communications. San Diego: Academic Press Inc. Elsevier B.V., v. 324, n. 2, p. 661-666, 2004.
dc.identifier0006-291X
dc.identifierhttp://hdl.handle.net/11449/34987
dc.identifier10.1016/j.bbrc.2004.09.109
dc.identifierWOS:000224794000028
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3907017
dc.description.abstractRoscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no crystallographic structure is available for complexes of CDK1 with inhibitors. The present work describes two molecular models for the binary complexes CDK1:roscovitine and CDK1:flavopiridol. These structural models indicate that both inhibitors strongly bind to the ATP-binding pocket of CDKI and structural comparison of the CDK complexes correlates the structures with differences in inhibition of these CDKs by flavopiridol and roscovitine. This article explains the structural basis for the observed differences in activity of these inhibitors. (C) 2004 Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationBiochemical and Biophysical Research Communications
dc.relation2.559
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectCDK
dc.subjectdrug design
dc.subjectFlavopiridol
dc.subjectRoscovitine
dc.subjecthomology modeling
dc.titleMolecular models of cyclin-dependent kinase 1 complexed with inhibitors
dc.typeArtigo


Este ítem pertenece a la siguiente institución